Finerenone, Eplerenone, and Spironolactone in HFpEF: A Bayesian Network Meta-Analysis of Efficacy and Safety
In HFpEF/HFmrEF, finerenone was the only MRA to significantly reduce hospitalization for HF, while no agent significantly reduced cardiovascular mortality and hyperkalemia risk increased across therapies. Overall, finerenone may offer the most favorable efficacy-safety balance among MRAs, pending confirmation in larger dedicated trials.
Authors
- Caroline de Oliveira Fischer Bacca (ORCID: https://orcid.org/0000-0002-4298-8649)
- P. K. A. Batista
- M V Gambetta
- Samantha Cristiane Lopes
- Helena Schell dos Santos
- Juliana Giorgi
- Vitor Bagattoli
Institutions
- Universidade Federal da Paraíba (BR)
- Hospital Israelita Albert Einstein (BR)
- Universidade para o Desenvolvimento do Alto Vale do Itajaí (BR)
- Hospital Sírio-Libanês (BR)
- University Alto Vale do Rio do Peixe (BR)
Publication Details
- Journal
- European Journal of Heart Failure
- Published
- 2026-03-12
- DOI
- https://doi.org/10.1093/ejhf/xuag083
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 0.00